On November 3, 2026, 3M announced a $7.35 billion nominal commitment, $5.8 billion in present value, to resolve about 99% of current PFAS personal injury claims. Payments run through 2034 and cover roughly 115,000 to 120,000 plaintiffs, inside and outside the federal AFFF (aqueous film-forming foam) multidistrict litigation in South Carolina. 3M will book a $5.8 billion pretax charge in the fourth quarter. Insurance Journal reports that plaintiffs allege kidney and testicular cancer, thyroid disease, and ulcerative colitis, and that individual payouts will vary.
The headline total is not the useful number for a risk manager. The per-claimant value and the payment curve are.
The arithmetic (lossreserves.com calculation, not a 3M figure)
Dividing the disclosed totals by the disclosed plaintiff range gives three rough benchmarks:
- Nominal, full amount: about $61,000 to $64,000 per claimant ($7.35 billion over 120,000 to 115,000 plaintiffs).
- Nominal, excluding the $680 million fund: about $56,000 to $58,000. The release says the $680 million is a reserve fund inside the commitment; it does not say how the fund is allocated, so treat this line as an assumption.
- Present value: about $48,000 to $50,000.
These are averages across a heterogeneous pool. Low-acuity files will settle below them and the cancer files above them. The average is useful as a sanity check on an average case reserve, not as a value for any one claim. The release does not disclose a claim-level grid, attorney fees, or lien treatment, so net-to-claimant values are unknown.
The payment curve
The schedule is $50 million in 2026, nothing in 2027, and about 20% of payments in the final two years. Insurance Journal says it is built to align with 3M’s other legacy settlement obligations, so it reflects the payer’s cash planning, not claim maturity. Compare the 2023 public water supplier settlement of up to $12.5 billion over 13 years, which was a different claimant class.
Who it affects
Self-insured entities with PFAS or AFFF in their own retentions: municipal fire departments and airports that stocked or discharged foam, public water and wastewater utilities, and manufacturers with products-liability self-insured retentions. Utilities already faced a separate opt-out clock on the water system settlements; this deal covers bodily injury, not water system property claims. Defendants other than 3M are not covered by the release, and the filing does not say which ones join.
Reserve mechanism: severity and development pattern
The deal moves two levers. Severity: a documented per-claimant benchmark now exists, so a case reserve far below it needs a written reason (different exposure route, different alleged condition, a weaker causation record). Development: a long, back-loaded curve means paid-to-incurred ratios on a similar settlement will look low for years. Discounting matters too; the gap between 3M’s nominal and present value figures is about 21%, and the same gap applies to any entity that settles on a comparable schedule and discounts reserves.
The $680 million fund and the anticipated MDL order on evidentiary and timing requirements for plaintiffs who do not join are the tail signals. 3M can walk away if participation falls below an undisclosed level, so late-reported claim frequency stays an open assumption. See the public entity GL IBNR guide, tail factors for captives, and the earlier mass tort reserve read from CNA.
Our read
Expect the $50,000 to $64,000 range to be cited in plaintiff demands against other AFFF defendants and municipal users within months, and expect case reserves set under $25,000 on cancer-alleged files to draw challenge at the next audit. Direction of risk: upward on severity for retained PFAS injury files, with payment timing pushed out rather than pulled in. This is judgment from the disclosed totals, not a prediction of any court outcome.
What this means for your next review
Ask your actuary to show PFAS or AFFF-attributed claims as their own row in the triangle, compare the average case reserve with the $50,000 to $64,000 range, and state the payment pattern and discount rate assumed. See case reserve strengthening for the documentation standard.
Watch next
3M’s November 4 investor call, the participation threshold and opt-in deadlines in the full 8-K, the MDL order on non-participating plaintiffs, and the Q4 charge.
Sources
- 3M press release, Form 8-K exhibit, November 3, 2026: https://www.sec.gov/Archives/edgar/data/0000066740/000006674026000318/pressrelease-xnov2026xv2.htm
- 3M Form 8-K, November 3, 2026: https://www.sec.gov/Archives/edgar/data/0000066740/000006674026000318/mmm-20261103.htm
- Insurance Journal, November 4, 2026: https://www.insurancejournal.com/news/national/2026/11/04/891433.htm